NAYA Biosciences Common Stock (IVF) has a profit margin of -122.68%, below the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
As of the most recent data (June 2026), IVF shows a profit margin of -122.68%. That compares with -319.37% in the prior-year period — up 61.6% year over year. That is below the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, IVF's profit margin is now -122.68% (was -319.37%) — a 61.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NAYA Biosciences Common Stock is outperforming or lagging.
The Healthcare sector average profit margin is about 13.89%. NAYA Biosciences Common Stock is at -122.68%, which is lower that average. That is roughly 983.0% below the sector mean. Use the comparison chart on this page to see how IVF stacks up against individual peers as well.
That compares with -319.37% in the prior-year period — up 61.6% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare NAYA Biosciences Common Stock with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has NAYA Biosciences Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -122.68%) with ownership activity and broader fundamentals.